Advertisement

Clinical and Translational Oncology

, Volume 20, Issue 7, pp 853–861 | Cite as

Preoperative plasma fibrinogen is associated with poor prognosis in esophageal carcinoma: a meta-analysis

  • G. Y. Lv
  • Y. Yu
  • L. An
  • X. D. Sun
  • D. W. Sun
Research Article

Abstract

Purpose

The aim of this meta-analysis was to investigate preoperative plasma fibrinogen (PPF) as a prognostic marker in esophageal carcinoma (EC) by meta-analysis.

Methods

Relevant studies were sought in the databases including Pubmed, Web of Science, Cochrane library, and Wanfang databases up to Oct 10th, 2017. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were used as effective value, and pooled HRs were synthesized by STATA 14.0 to assess the prognostic impact of PPF on EC patients.

Results

A total of 8 studies with 2827 patients were collected in this meta-analysis. Our results revealed that high PPF was significantly associated with poor OS (HR = 1.90, 95% CI 1.56–2.33, P = 0.000; HR = 1.76, 95% CI 1.28–2.42, P = 0.000) and poor DFS (HR = 1.91, 95% CI 1.50–2.43, P = 0.000; HR = 1.51, 95% CI 1.16–1.97, P = 0.000) in EC patients from univariate and multivariate analysis results, respectively, which suggested that EC patients with high PPF will suffer from high postoperative mortality and recurrence rate.

Conclusion

High PPF was significantly associated with poor OS and DFS in EC patients. Fibrinogen can serve as a prognostic marker and even a future targeting molecule during the treatment of EC patients.

Keywords

Preoperative plasma fibrinogen (PPF) Esophageal carcinoma (EC) Prognosis Meta-analysis 

Notes

Compliance with ethical standards

Conflict of interests

All the authors declare there is no conflict of interest in this research.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505–27.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Lordick F. Treatment of oesophageal cancer—stressing the patient perspective. Eur J Cancer. 2017;84:360–2.  https://doi.org/10.1016/j.ejca.2017.08.021.CrossRefPubMedGoogle Scholar
  3. 3.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Otten HM, Prins MH. Venous thromboembolism and occult malignancy. Thromb Res. 2001;102(6):V187–94.CrossRefPubMedGoogle Scholar
  5. 5.
    Kołodziejczyk J, Ponczek MB. The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression. Contemp Oncol (Pozn). 2013;17(2):113–9.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Falanga A, Russo L, Milesi V, Vignoli A. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol. 2017;118:79–83.CrossRefPubMedGoogle Scholar
  7. 7.
    Ebrahimi S, Rahmani F, Behnam-Rassouli R, Hoseinkhani F, Parizadeh MR, Keramati MR, et al. Proinflammatory signaling functions of thrombin in cancer. J Cell Physiol. 2017;232(9):2323–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Blombäck B, Blombäck M. The molecular structure of fibrinogen. Ann NY Acad Sci. 1972;8(202):77–97.CrossRefGoogle Scholar
  9. 9.
    Pulanić D, Rudan I. The past decade: fibrinogen. Coll Antropol. 2005;29(1):341–9.PubMedGoogle Scholar
  10. 10.
    Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2012;34(1):43–62.CrossRefPubMedGoogle Scholar
  11. 11.
    Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol. 2009;22(1):49–60.CrossRefPubMedGoogle Scholar
  12. 12.
    Simpson-Haidaris PJ, Rybarczyk B. Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann NY Acad Sci. 2001;936:406–25.CrossRefPubMedGoogle Scholar
  13. 13.
    Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.CrossRefPubMedGoogle Scholar
  14. 14.
    Sampson MT, Kakkar AK. Coagulation proteases and human cancer. Biochem Soc Trans. 2002;30(2):201–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Perisanidis C, Psyrri A, Cohen EE, Engelmann J, Heinze G, Perisanidis B, et al. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis. Cancer Treat Rev. 2015;41(10):960–70.CrossRefPubMedGoogle Scholar
  16. 16.
    Ilhan-Mutlu A, Starlinger P, Perkmann T, Schoppmann SF, Preusser M, Birner P. Plasma fibrinogen and blood platelet counts are associated with response to neoadjuvant therapy in esophageal cancer. Biomark Med. 2015;9(4):327–35.CrossRefPubMedGoogle Scholar
  17. 17.
    Wang J, Liu H, Shao N, Tan B, Song Q, Jia Y, et al. The clinical significance of preoperative plasma fibrinogen level and platelet count in resectable esophageal squamous cell carcinoma. World J Surg Oncol. 2015;22(13):157.  https://doi.org/10.1186/s12957-015-0543-4.CrossRefGoogle Scholar
  18. 18.
    Matsuda S, Takeuchi H, Fukuda K, Nakamura R, Takahashi T, Wada N, et al. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment. Dis Esophagus. 2014;27(7):654–61.CrossRefPubMedGoogle Scholar
  19. 19.
    Altman DG. Systematic reviews of evaluations of prognostic variables. BMJ. 2001;323(7306):224–8.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Stang A. Critical evaluation of the Newcastle–Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Sun XD, Shi XJ, Chen YG, Wang CL, Ma Q, Lv GY. Elevated preoperative neutrophil–lymphocyte ratio is associated with poor prognosis in hepatocellular carcinoma patients treated with liver transplantation: a meta-analysis. Gastroenterol Res Pract. 2016;2016:4743808.  https://doi.org/10.1155/2016/4743808 (Epub 2015 Dec 30).PubMedCrossRefGoogle Scholar
  22. 22.
    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhang F, Wang Y, Sun P, Wang ZQ, Wang DS, Zhang DS, et al. Fibrinogen promotes malignant biological tumor behavior involving epithelial–mesenchymal transition via the p-AKT/p-mTOR pathway in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2017;.  https://doi.org/10.1007/s00432-017-2493-4.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wakatsuki K, Matsumoto S, Migita K, Ito M, Kunishige T, Nakade H, et al. Preoperative plasma fibrinogen is associated with lymph node metastasis and predicts prognosis in resectable esophageal cancer. World J Surg. 2017;41(8):2068–77.CrossRefPubMedGoogle Scholar
  27. 27.
    Zhang SS, Lei YY, Cai XL, Yang H, Xia X, Luo KJ, et al. Preoperative serum fibrinogen is an independent prognostic factor in operable esophageal cancer. Oncotarget. 2016;7(18):25461–9.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Qiao CR, Zhao S, Li XN, Zhao J, Zhu DY, Wu K, et al. The prognostic and clinicopahtological role of peripheral plasma fibrinogen and platelete in esophageal squamous cell carcinoma. Chin J of Gerontol. 2016;1(36):348–50 (Article in Chinese).Google Scholar
  29. 29.
    Zhang D, Zhou X, Bao W, Chen Y, Cheng L, Qiu G, et al. Plasma fibrinogen levels are correlated with postoperative distant metastasis and prognosis in esophageal squamous cell carcinoma. Oncotarget. 2015;6(35):38410–20.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Arigami T, Okumura H, Matsumoto M, Uchikado Y, Uenosono Y, Kita Y, et al. Analysis of the fibrinogen and neutrophil-lymphocyte ratio in esophageal squamous cell carcinoma: a promising blood marker of tumor progression and prognosis. Medicine (Baltimore). 2015;94(42):e1702.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Takeuchi H, Ikeuchi S, Kitagawa Y, Shimada A, Oishi T, Isobe Y, et al. Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol. 2007;22(12):2222–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Kijima T, Arigami T, Uchikado Y, Uenosono Y, Kita Y, Owaki T, et al. Combined fibrinogen and neutrophil–lymphocyte ratio as a prognostic marker of advanced esophageal squamous cell carcinoma. Cancer Sci. 2017;108(2):193–9.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Suzuki T, Shimada H, Nanami T, Oshima Y, Yajima S, Washizawa N, et al. Prognostic significance of hyperfibrinogenemia in patients with esophageal squamous cell carcinoma. Int J Clin Oncol. 2017;22(3):461–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Tan Z, Zhang M, Han Q, Wen J, Luo K, Lin P, et al. A novel blood tool of cancer prognosis in esophageal squamous cell carcinoma: the fibrinogen/albumin ratio. J Cancer. 2017;8(6):1025–9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Li XH, Wang XP, Gu WS, Lin JH, Huang H, Kang T, et al. Clinical significance of preoperative thrombin time in patients with esophageal squamous cell carcinoma following surgical resection. PLoS ONE. 2015;10(10):e0140323.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Wayman J, O’Hanlon D, Hayes N, Shaw I, Griffin SM. Fibrinogen levels correlate with stage of disease in patients with oesophageal cancer. Br J Surg. 1997;84(2):185–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Zhao C, Su Y, Zhang J, Feng Q, Qu L, Wang L, et al. Fibrinogen-derived fibrinostatin inhibits tumor growth through anti-angiogenesis. Cancer Sci. 2015;106(11):1596–606.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Palumbo JS, Kombrinck KW, Drew AF, Grimes TS, Kiser JH, Degen JL, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96(10):3302–9.PubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2017

Authors and Affiliations

  1. 1.Department of Hepatobiliary and Pancreatic SurgeryThe First Hospital of Jilin UniversityChangchunChina
  2. 2.Department of DermatologyChina-Japan Union Hospital of Jilin UniversityChangchunChina

Personalised recommendations